2023
Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice
Lee S, Schleer H, Park H, Jang E, Boyer M, Tao B, Gamez-Mendez A, Singh A, Folta-Stogniew E, Zhang X, Qin L, Xiao X, Xu L, Zhang J, Hu X, Pashos E, Tellides G, Shaul P, Lee W, Fernandez-Hernando C, Eichmann A, Sessa W. Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice. Nature Cardiovascular Research 2023, 2: 438-448. PMID: 39196046, PMCID: PMC11358031, DOI: 10.1038/s44161-023-00266-2.Peer-Reviewed Original ResearchLDL transcytosisLDL receptor knockout miceReceptor knockout miceAtherosclerotic cardiovascular diseaseLow-density lipoprotein accumulationHigh-fat dietPromising therapeutic strategyTherapeutic neutralizationMacrophage infiltrationTriglyceride levelsLDL entryCardiovascular diseaseSelective monoclonal antibodiesLipoprotein accumulationTherapeutic strategiesKnockout micePlaque formationAtherosclerosis initiationType 1Genetic deletionArterial wallMonoclonal antibodiesEndothelial cellsLDL accumulationMiceLonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome
Murtada S, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra A, Li D, Braddock D, Tellides G, Gordon L, Humphrey J. Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome. ELife 2023, 12: e82728. PMID: 36930696, PMCID: PMC10023154, DOI: 10.7554/elife.82728.Peer-Reviewed Original ResearchConceptsMouse modelLeft ventricular diastolic functionHutchinson-Gilford progeria syndromeVentricular diastolic functionPulse wave velocityDrug-associated effectsMTOR inhibitor rapamycinCardiovascular sequelaeDiastolic functionProgeria syndromeDevastating conditionCardiac functionCardiovascular functionClinical trialsCardiovascular diseaseMuscular arteriesUS FoodDrug AdministrationProgeria miceArterial structurePremature deathLonafarnibCardiovascular structureCharacteristics of agingInhibitor rapamycin
2015
MHC class II-disparate heart but not skin allografts accelerate recipient cardiovascular disease (TRAN1P.934)
Zhou J, yi T, Qin L, Ali R, Li Q, Jiao Y, Li G, Zhang J, Sadeghi M, Pober J, Tellides G. MHC class II-disparate heart but not skin allografts accelerate recipient cardiovascular disease (TRAN1P.934). The Journal Of Immunology 2015, 194: 140.16-140.16. DOI: 10.4049/jimmunol.194.supp.140.16.Peer-Reviewed Original ResearchSkin allograftsCardiovascular diseaseAllograft rejectionCardiac allograftsHeart allograftsDonor miceSkin graftsMHC classAtherosclerotic lesionsApoE-/- mouse modelEarly activation marker CD69End-stage organ failureCD4 T cellsWeeks post transplantationActivation marker CD69Larger atherosclerotic lesionsHeart isograftsCardiac isograftsOrgan failurePost transplantationIL-12ACardiac functionElevated mRNA levelsEffective therapyOrgan transplantation